These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 39131157)

  • 21. A prospective humoral immune monitoring study of kidney transplant recipients receiving three doses of SARS-CoV-2 mRNA vaccine.
    Borgogna C; Ferrante D; Rosso G; Guglielmetti G; Lo Cigno I; Raviola S; Caneparo V; Quaglia M; Cantaluppi V; Gariglio M
    J Med Virol; 2024 Jun; 96(6):e29710. PubMed ID: 38804187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice.
    Slamanig S; González-Domínguez I; Chang LA; Lemus N; Lai TY; Martínez JL; Singh G; Dolange V; Abdeljawad A; Kowdle S; Noureddine M; Warang P; Singh G; Lee B; García-Sastre A; Krammer F; Schotsaert M; Palese P; Sun W
    EBioMedicine; 2024 Jul; 105():105185. PubMed ID: 38848648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The contributions of vaccination and natural infection to the production of neutralizing antibodies against the SARS-CoV-2 prototype strain and variants.
    Xie H; Zhang J; Bai S; Lv M; Li J; Chen W; Suo L; Chen M; Zhao W; Zhou S; Wang J; Zhang A; Ma J; Wang F; Yan L; Li D; Wu J
    Int J Infect Dis; 2024 Jul; 144():107060. PubMed ID: 38670482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
    Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
    J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
    Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
    Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Age-Related Differences in Neutralizing Antibody Responses against SARS-CoV-2 Delta and Omicron Variants in 151 SARS-CoV-2-Naïve Metropolitan Residents Boosted with BNT162b2.
    Lee B; Bae GE; Jeong IH; Kim JH; Kwon MJ; Kim J; Kim B; Lee JW; Nam JH; Huh HJ; Kang ES
    J Appl Lab Med; 2024 Jul; 9(4):741-751. PubMed ID: 38531067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity.
    Tejedor Vaquero S; de Campos-Mata L; Ramada JM; Díaz P; Navarro-Barriuso J; Ribas-Llaurado C; Rodrigo Melero N; Carolis C; Cerutti A; Gimeno R; Magri G
    Front Immunol; 2021; 12():737083. PubMed ID: 34539673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds.
    Usdan L; Patel S; Rodriguez H; Xu X; Lee DY; Finn D; Wyper H; Lowry FS; Mensa FJ; Lu C; Cooper D; Koury K; Anderson AS; Türeci Ö; Şahin U; Swanson KA; Gruber WC; Kitchin N;
    Clin Infect Dis; 2024 May; 78(5):1194-1203. PubMed ID: 38016021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
    Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
    Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Favourable humoral but reduced cellular immune response to COVID-19 mRNA BNT162b2 vaccine in patients with childhood-onset systemic lupus erythematosus.
    Karabag Yilmaz E; Agbas A; Canpolat N; Gunalp A; Sahin S; Ozbey D; Gulmez R; Saygili SK; Kocazeybek B; Kasapcopur O; Caliskan S
    Lupus Sci Med; 2024 Sep; 11(2):. PubMed ID: 39306341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients' subgroups.
    Ferri C; Ursini F; Gragnani L; Raimondo V; Giuggioli D; Foti R; Caminiti M; Olivo D; Cuomo G; Visentini M; Cacciapaglia F; Pellegrini R; Pigatto E; Urraro T; Naclerio C; Tavoni A; Puccetti L; Varcasia G; Cavazzana I; L'Andolina M; Ruscitti P; Vadacca M; Gigliotti P; La Gualana F; Cozzi F; Spinella A; Visalli E; Dal Bosco Y; Amato G; Masini F; Pagano Mariano G; Brittelli R; Aiello V; Caminiti R; Scorpiniti D; Rechichi G; Ferrari T; Monti M; Elia G; Franceschini F; Meliconi R; Casato M; Iannone F; Giacomelli R; Fallahi P; Santini SA; Zignego AL; Antonelli A
    J Autoimmun; 2021 Dec; 125():102744. PubMed ID: 34781162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Follow-up SARS-CoV-2 serological study of a health care worker cohort following COVID-19 booster vaccination.
    Hönning A; Tomczyk S; Hermes J; Grossegesse M; Hofmann N; Michel J; Neumann M; Nitsche A; Hoppe B; Eckmanns T; Schmidt-Traub H; Zappel K
    BMC Infect Dis; 2024 Apr; 24(1):436. PubMed ID: 38658874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteomic and Cellular Characterization of Omicron Breakthrough Infections and a Third Homologous or Heterologous Boosting Vaccination in a Longitudinal Cohort.
    Zhang Y; Fu Z; Zhang H; Lin K; Song J; Guo J; Zhang Q; Yuan G; Wang H; Fan M; Zhao Y; Sun R; Guo T; Jiang N; Qiu C; Zhang W; Ai J
    Mol Cell Proteomics; 2024 Jun; 23(6):100769. PubMed ID: 38641227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
    Oda Y; Kumagai Y; Kanai M; Iwama Y; Okura I; Minamida T; Yagi Y; Kurosawa T; Greener B; Zhang Y; Walson JL
    Lancet Infect Dis; 2024 Apr; 24(4):351-360. PubMed ID: 38141632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Humoral response after mRNA COVID-19 primary vaccination and single booster dose in people living with HIV compared to controls: A French nationwide multicenter cohort study-ANRS0001s COV-POPART.
    Loubet P; Lelievre JD; François A; Botelho-Nevers E; Chidiac C; Chirio D; Dubee V; Dussol B; Galtier F; Hessamfar M; Hodaj E; Jaffuel S; Lacombe K; Laine F; Lefebvre M; Maakaroun-Vermesse Z; Makinson A; Portefaix A; Pourcher V; Rey D; Zucman D; Longobardi J; Bertheau M; Tartour E; de Lamballerie X; Launay O; Wittkop L;
    Int J Infect Dis; 2024 Sep; 146():107110. PubMed ID: 38825164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2.
    Braun-Moscovici Y; Kaplan M; Braun M; Markovits D; Giryes S; Toledano K; Tavor Y; Dolnikov K; Balbir-Gurman A
    Ann Rheum Dis; 2021 Oct; 80(10):1317-1321. PubMed ID: 34144967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Loss of Pfizer (BNT162b2) Vaccine-Induced Antibody Responses against the SARS-CoV-2 Omicron Variant in Adolescents and Adults.
    Gupta SL; Mantus G; Manning KE; Ellis M; Patel M; Ciric CR; Lu A; Turner JS; O'Halloran JA; Presti RM; Joshi DJ; Ellebedy AH; Anderson EJ; Rostad CA; Suthar MS; Wrammert J
    J Virol; 2022 Sep; 96(17):e0058222. PubMed ID: 35976000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors Associated with Neutralizing Antibody Responses following 2-Dose and 3rd Booster Monovalent COVID-19 Vaccination in Japanese People Living with HIV.
    Ngare I; Tan TS; Toyoda M; Kuwata T; Takahama S; Nakashima E; Yamasaki N; Motozono C; Fujii T; Minami R; Barabona G; Ueno T
    Viruses; 2024 Apr; 16(4):. PubMed ID: 38675897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Humoral responses to multiple SARS-CoV-2 variants after two doses of vaccine in kidney transplant patients.
    Du PX; Chang SS; Ho TS; Shih HC; Tsai PS; Syu GD
    Virulence; 2024 Dec; 15(1):2351266. PubMed ID: 38717195
    [No Abstract]   [Full Text] [Related]  

  • 40. Humoral immunity to SARS-CoV-2 in kidney transplant recipients and dialysis patients: IgA and IgG patterns unraveled after SARS-CoV-2 infection and vaccination.
    De Bouver C; Bouziotis J; Wijtvliet VPWM; Ariën KK; Mariën J; Heyndrickx L; Couttenye MM; de Fijter HJW; Mestrez F; Treille S; Mat O; Collart F; Allard SD; Vingerhoets L; Moons P; Abramowicz D; De Winter BY; Pipeleers L; Wissing KM; Ledeganck KJ
    Virol J; 2024 Jun; 21(1):138. PubMed ID: 38872127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.